The PrEP Costing Guidelines provide a framework for estimating the cost of providing pre-exposure prophylaxis (PrEP), which is the use of antiretroviral (ARV) drugs for preventing the acquisition of HIV infection. They are intended to provide a PrEP-specific resource for costing that could be accessible to individuals tasked with collecting, evaluating, and utilizing cost data, and who may have differing levels of familiarity with economics.
The PrEP Costing Guidelines have three principal aims: (1) Support the estimation of the full and incremental total cost and unit cost of adding PrEP to existing HIV or other health services; (2) Address some of the challenges faced by costing experts who are specifically assessing the costs of PrEP; and, (3) Improve the quality, interpretation and use of PrEP cost estimates through improved consistency and transparency of methods, assumptions and reporting.
Normative Guidance/Policies, Service Delivery, Vertical Transmission
Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…
Nigeria HIV Oral PrEP Job Aids & SOPs
See these job aids and SOPs for flow charts explaining the stages that PrEP clients go through, the role of a provider in this process, information on which documents will most smoothly allow providers to register patients on PrEP, guidance on vital service delivery points, and how to assess risk stratification of potential PrEP clients.
Development of a Relationship Counselling Website to Identify and Mitigate Risk of Intimate Partner Violence in the Context of Women’s PrEP Use
This article from PLOS Digital Health discusses the results of beta-testing CHARISMA mobile, a digital resource to support lay counsellors help women access PrEP safely and and effectively by addressing dynamics of their relationships with male partners, including exposure to intimate partner violence. Click here for more information on CHARISMA.
ICAP PrEP Package
The PrEP Package was developed by ICAP at Columbia University to support the implementation of PrEP. The training curriculum and tools, including tools for monitoring and evaluation, were designed to enable clinical providers to attain the skills required to provide PrEP to appropriate candidates in an effective and safe manner. The training materials serve as…
V Branding Campaign
“V” is a branding campaign developed in South Africa as part of Project Emotion, awarded in 2015, to support increased uptake and adherence to oral PrEP among adolescent girls and young women. View the research and background and campaign overview briefs for more information. Zimbabwe adaptations In 2020, the V Campaign, originally conceptualized in South…
Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: A multi-country qualitative analysis
This article from AIDS and Behavior explores adolescent girls and young women’s experiences in disclosing use of oral PrEP and the dapivirine vaginal ring in South Africa, Uganda, and Zimbabwe.
PrEP Category Positioning Strategy for Adolescent Girls and Young Women
MOSAIC has developed an approach to building a PrEP Category Positioning Strategy for Adolescent Girls and Young Women. Available soon, the final strategy is intended for use by implementers to guide their development of national communications strategies, demand-generation campaigns, or other marketing materials for the expanding category of PrEP products.
Baseline Preferences for Oral Pre-Exposure Prophylaxis (PrEP) or Dapivirine Intravaginal Ring for HIV Prevention Among Adolescent Girls and Young Women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 Study)
This journal article from PLOS ONE explored baseline preferences for oral PrEP or the dapivirine ring for AGYW (adolescent girls and young women) in South Africa, Uganda, and Zimbabwe.
Cumulative Number of PrEP Initiations for Q1 of 2023
The attached resource is the cumulative number of PrEP initiations for Q1 of 2023.
Country Planning for Product Introduction Matrix
AVAC’s Country Planning for Product Introduction Matrix tracks the regulatory status of cabotegravir for PrEP and the dapivirine vaginal ring, along with related late stage clinical trials and implementation research, procurement plans, and oral PrEP provision across lower and middle income countries.